Aerovate Therapeutics (NASDAQ:AVTE) Issues Earnings Results

Aerovate Therapeutics (NASDAQ:AVTE) released its quarterly earnings results on Tuesday. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.03, Zacks reports.

Aerovate Therapeutics Stock Down 0.8 %

AVTE traded down $0.02 during midday trading on Thursday, hitting $2.61. The company had a trading volume of 103,306 shares, compared to its average volume of 617,010. Aerovate Therapeutics has a 52 week low of $1.25 and a 52 week high of $32.42. The company has a market capitalization of $75.35 million, a price-to-earnings ratio of -0.88 and a beta of 1.00. The stock’s 50 day moving average price is $2.18 and its 200 day moving average price is $6.33.

Aerovate Therapeutics Company Profile

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.